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Abstract
Possible pathophysiological, clinical and epidemiological interactions between human immunodeﬁciency virus (HIV) and tropical pathogens,
especially malaria parasites, constitute a concern in tropical areas. Two decades of research have shown that HIV-related
immunosuppression is correlated with increased malaria infection, burden, and treatment failure, and with complicated malaria,
irrespective of immune status. The recent role out of antiretroviral therapies and new antimalarials, such as artemisinin combination
therapies, raise additional concerns regarding possible synergistic and antagonistic effects on efﬁcacy and toxicity. Co-trimoxazole, which is
used to prevent opportunistic infections, has been shown to have strong antimalarial prophylactic properties, despite its long-term use and
increasing antifolate resistance. The administration of efavirenz, a non-nucleoside reverse transcriptase inhibitor, with amodiaquine–
artesunate has been associated with increased toxicity. Recent in vivo observations have conﬁrmed that protease inhibitors have strong
antimalarial properties. Ritonavir-boosted lopinavir and artemether–lumefantrine have a synergistic effect in terms of improved malaria
treatment outcomes, with no apparent increase in the risk of toxicity. Overall, for the prevention and treatment of malaria in HIV-infected
populations, the current standard of care is similar to that in non-HIV-infected populations. The available data show that the wider use of
insecticide-treated bed-nets, co-trimoxazole prophylaxis and antiretroviral therapy might substantially reduce the morbidity of malaria in
HIV-infected patients. These observations show that those accessing care for HIV infection are now, paradoxically, well protected from
malaria. These ﬁndings therefore highlight the need for conﬁrmatory diagnosis of malaria in HIV-infected individuals receiving these
interventions, and the provision of different artemisinin-based combination therapies to treat malaria only when the diagnosis is conﬁrmed.
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Introduction
Since it became obvious that resource-poor regions of the
world, and in particular south-eastern Africa, carry the main
burden of the human immunodeﬁciency virus (HIV) pandemic,
there have been concerns about possible pathophysiological,
clinical and epidemiological interactions between HIV and
tropical pathogens. Especially Plasmodium falciparum malaria,
one of the main tropical killers was envisaged as concomitantly
malaria treatment and control were undermined by the
emergence of resistance to commonly used antimalarial drugs
such as chloroquine and sulphadoxine–pyrimethamine. The
geographical distribution of HIV and malaria suggests that, for
many sub-Saharan African countries, even a small link between
the two diseases would be of extreme importance in terms of
public health impact and control policies. Considering that the
two diseases share similar immunological factors, such a link
may be plausible, and needs to be assessed carefully. Further-
more, as malaria is not the only disease that could interact with
HIV-1, information from malaria–HIV studies may be relevant
for other parasitic, bacterial and viral co-infections. We
present a short review of the literature, and attempt to
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reiterate the reasons for the above-mentioned concerns, to
assemble the available evidence, and to address outstanding or
possible future questions and concerns.
Pathophysiology
The impact of HIV infection on malaria
Most clinical problems in HIV-1-infected individuals are related
to the speciﬁc loss of pathogen-speciﬁc CD4 cell immunity of
the Th1 type, and, in developing/tropical countries, tubercu-
losis is probably the most common consequence of Th1
depletion [1,2]. Other protozoan parasites are often contrib-
utors to mortality in individuals with AIDS: Babesia, Toxo-
plasma, Giardia, Cryptosporidium, Isospora, and Leishmania [3,4].
As acquired immunity to blood-stage malaria was thought to
be primarily antibody-mediated, one might predict that it
would be largely unaffected, particularly as cytokine patterns in
HIV-infected individuals are said to be associated with a shift to
Th2-type responses [5]. B-cell polyclonal expansion and total
immunoglobulin concentrations, including antimalarial antibod-
ies, in HIV-1-infected patients can be higher than or the same
as those in uninfected controls, [3,6]. Today, we know that
HIV-1 CD4 T-cells, the prime targets for destruction by HIV-1,
have a critical role in both Th1-type and Th2-type responses to
malaria [4]. Enhanced T-cell activation in co-infected patients
can worsen the immune response to both diseases [7].
Phagocytosis, proliferative and Th1 cytokine responses are
reduced in pregnant women with HIV infection, and pregnancy
may contribute to impaired control of malaria in HIV-infected
individuals [8]. However, variant surface antigen antibody
levels, which seem important for the control of parasite
density and treatment outcome, seem to be marginally or not
affected by HIV-1 in non-pregnant adults [9]. In pregnancy,
although antimalarial antibody responses are mostly unaltered,
there seem to be impaired responses to some antigens,
including variant surface antigens expressed on infected
erythrocytes binding chondroitin sulfate A, a key receptor
for placental sequestration. This impairment is greatest in
women with more advanced HIV disease, and occurs across all
gravidities and in women with and without current malaria
infection [10].
The impact of malaria infection on HIV
The HIV-1 life cycle is intimately related to the level of
activation of the immune cells supporting viral replication,
which is enhanced by increased viral cellular entry, and reverse
and proviral transcription [11]. Malaria infection is associated
with strong CD4 cell activation and upregulation of proin-
ﬂammatory cytokines; it provides the ideal microenvironment
for the spread of the virus among the CD4 cells and for rapid
HIV-1 replication [12]. In a malaria challenge trial, enhanced
HIV production was related to the development of antimalaria
immunity, and may have been mediated by proinﬂammatory
cytokines [13]. HIV-1 viral load ﬁrst increases in malaria-in-
fected patients, and then decreases 4 weeks after antimalaria
treatment [14]. Malaria parasitaemia also has an immediate
impact on CD4 cells. Indeed, malaria in children is associated
with reversible lymphopenia and an absolute lower CD4 cell
count [15,16], and this has also been observed in HIV-1-in-
fected adults [17]. Similar observations have been made in
malaria-infected pregnant women. For example, the expres-
sion of CC-chemokine receptor 5, a co-receptor for HIV cell
entry, is increased in the placentas of malaria-infected women,
possibly contributing to intrauterine HIV transmission [18].
Malaria-infected pregnant women have an increased viral load,
although lower than that observed in non-pregnant adults [19–
21]. Of special concern is the risk of mother-to-child
transmission (MTCT). Maternal HIV-1 viral load is currently
considered to be the single most important determinant of
MTCT. Studies addressing this issue produced conﬂicting
results, and were all conducted prior to the introduction of
antiretrovirals (ARVs) in Africa [18–22]. The discrepant results
are probably attributable to the differences in diagnosing
placental malaria, but might also reﬂect the complexity of
maternal immune responses to malaria, which, on the one
hand, may stimulate HIV viral replication in the placenta,
thereby increasing the local viral load, and on the other hand
may potentially control the severity of malarial infection and
HIV replication [10]. The net result may be either an enhanced
or a reduced risk of MTCT, depending on the speciﬁc
situation. Furthermore, immunocompromised mothers with
malaria–HIV co-infection have altered chemokine and cytokine
proﬁles, less protective immune responses, and consequently
higher parasite densities and viral load, leading to an increased
risk of MTCT [23]. Today, schemes for the prevention of
MTCT have reduced the risk to almost zero, so, in an
interventional research setting, carefully designed studies,
probably with huge sample sizes, will be needed to assess a
modiﬁed risk of MTCT.
Epidemiology
Impact of malaria on HIV transmission
There is a strong correlation between viral load and the risk of
heterosexual HIV-1 transmission, the predominant mode of
transmission in Africa, and there is compelling evidence
suggesting an epidemiological synergy between sexually trans-
mitted infections and HIV [24,25]. Enhanced immune activation
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caused by malaria may contribute to increased HIV-1 trans-
mission and disease progression. Transient but repeated
elevated HIV viral loads resulting from recurrent co-infections,
such as malaria, could inﬂuence and increase HIV prevalence
[26]. However, we lack consistent data for some parameters
used to measure the impact of malaria on HIV transmission.
Only two reports have mentioned that HIV-1 viral load ﬁrst
increases in malaria-infected patients and then decreases
4 weeks after antimalarial treatment [14,27] (Fig. 1).
Impact of HIV on malaria transmission
At the population level, an impact of HIV on malaria
transmission is suggested by the fact that families living in the
same household as an HIV-infected individual have higher rates
of malaria among HIV-negative children than do families
without an HIV-infected individual in the household [28].
Mathematical modelling offers an alternative approach, and
can be applied to different malaria and HIV settings, provided
that the relevant parameters are included. Earlier models
focusing on the direct effects in HIV-infected people concluded
that the population-level effect was limited because of different
geographical distributions and contrasting age patterns of the
two diseases [29], and a second, more complex, model [26]
estimated that the largest epidemiological impact occurs when
the prevalence of one disease, HIV or malaria, is very high
while the other is low and near its endemic threshold.
However, when the prevalence of both diseases is either very
high or very low, the epidemiological impact of the interaction
will be minimal. The latter has been conﬁrmed by a review
evaluating multiple cross-sectional surveys in western sub-Sah-
aran Africa [30]. However, several points should be consid-
ered. First, a ‘minimal’ impact in a setting with a high double
burden will still be substantial in absolute terms. Second, with
no or inefﬁcacious treatment, the duration of heightened viral
load and increased prevalence of parasitaemia resulting from
HIV immunosuppression will be extended. Third, when both
diseases reach an epidemic equilibrium, even if the direct
epidemiological impact is minimal, interaction will occur
frequently; viraemia will increase in HIV-infected patients as
a result of malaria infection, and parasite load will also be
higher in immunosuppressed co-infected patients. Therefore,
co-infection is likely to produce a higher circulating biomass
and a higher biodiversity of both species [31]. Finally, a wide
variety of biological and behavioural factors are associated with
the risk of HIV-1 sexual transmission [32], and the malaria
morbidity effect on sexual behaviour is also not clearly
documented and is not a sensitive parameter in HIV
transmission models. No model has included indirect effects
attributable to concurrent malaria and HIV-1 infection, such as
anaemia or pregnancy, a vulnerable period for malaria
morbidity and mortality, and HIV transmission has been not
been considered. Therefore, the actual impact of the interac-
tion, in the absence of any control intervention, might be more
important than expected.
HIV-1 and malaria morbidity
A substantial overlap in the clinical and laboratory character-
istics of malaria and HIV-related syndromes generates
potential difﬁculties in AIDS staging and in the diagnosis and
management of patients at risk of co-infection [33]. Several
clinical or laboratory syndromes that are shared by malaria and
AIDS-related conditions and that might cause diagnostic
confusion have been identiﬁed [33]. For two decades, evidence
for the impact of HIV-1 on malaria has accumulated. Increased
risks of a higher parasite prevalence, malarial fever and clinical
malaria have been reported in HIV-infected adults, and the risk
was inversely correlated with the CD4 cell count [34,35]
(Fig. 1; Table 1). However, the relationship between malaria
and HIV-1 immunosuppression is more complex than
expected. The incidence of recurrent malaria (>28 days after
the ﬁrst episode) was not associated with a low CD4 cell
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FIG. 1. Clinical epidemiological impact of human immunodeﬁciency
virus (HIV)–malaria interactions.
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count [36], although a low CD4 cell count was associated with
increased parasite density in patients with clinical malaria but
not in people with asymptomatic parasite carriage [37].
Furthermore, for any parasite density, the probability of fever
was inversely related to CD4 cell count. In children, HIV
infection might be associated with severe malaria, although the
magnitude of the effect may be relatively small [38]. In adults
living in areas with low and unstable transmission, two-fold and
seven-fold increases in mortality were observed [39,40], and a
multifold increase was observed in an area of stable malaria
transmission [41]. In both adult studies, HIV was an indepen-
dent risk factor irrespective of CD4 cell count, although
patients with a low CD4 cell count had an increased risk in the
meso-endemic area. We should bear in mind that HIV-1
immunosuppression is associated with various opportunistic
infections, and any fever in these patients with a positive
malaria slide could be associated with an underlying disease
[30], and that malaria parasitaemia, especially if symptomatic,
transiently affects the CD4 cell count [17]. Because of the
epidemiological overlap, particularly in eastern and southern
Africa, co-infection with HIV-1 and malaria is a common
phenomenon. Anaemia is frequently observed in both individ-
uals with malaria and in those with HIV infection, although the
physiopathological mechanisms differ. It is the most frequent
cytopenia seen in HIV-infected individuals [42], partly because
of bone marrow suppression by medications [43] and other
factors, including haemolysis, gastrointestinal bleeding, nutri-
tional deﬁciencies [44], and a diminished erythropoietin
response [45]. Malaria is also often associated with anaemia,
and, during a malaria attack, HIV-1-infected individuals, both
infants and adults, have lower haemoglobin levels than
HIV-1-uninfected patients [46]. Moreover, HIV-1-infected
infants have an increased risk for severe anaemia [47].
Furthermore, HIV-1-infected malaria patients show a steeper
haemoglobin decline in the ﬁrst weeks after successful malaria
treatment, and show slower haematological recovery (Fig. 1).
Possibly, this slow recovery could be explained by the
impairments of erythropoiesis and iron mobilization [48].
Observations in pregnant mothers, sometimes including
their newborn children, have demonstrated an increased risk
of malaria in those with HIV infection. The risk increment is
more pronounced in multigravida than in primigravida,
indicating that HIV-1 hinders the development of immunity.
A two-fold increase in malaria incidence was also observed
[10]. The relative risk (RR) for malaria parasitaemia in
HIV-1-infected women has been estimated during pregnancy
(RR 1.58), at delivery (RR 1.65), and for placenta malaria
(RR 1.66). HIV-1 infection was also associated with lower
birthweight [49], higher infant mortality, and a four-fold
greater risk of malaria attacks in the newborn [50]. The
increased risk of placental malaria in HIV-infected mothers was
also associated with higher postnatal mortality [51]. As in
non-pregnancy, the risk of anaemia is beyond the degree that
would be expected from infections with malaria or HIV alone,
suggesting a synergistic interaction between HIV and malaria,
placing dually infected women at very high risk of developing
severe anaemia [49,52].
Malaria and HIV-1 Disease Progression
Malaria infection leads to strong CD4 cell activation [12]. The
selective infection of the antigen-speciﬁc memory CD4 cells by
HIV leads to the loss of these cells [11]. Therefore, HIV
patients could lose the de novo activated malaria-speciﬁc CD4
cells during each malaria attack, because these are more
susceptible to HIV, and they could progress more rapidly to
full-blown AIDS [53–55]. At present, there is no empirical
evidence for this, but modelling from empirical data suggests
that an additional 40 CD4 cells/lL per year may be lost
because of repeated malaria episodes [54].
Case Management
Artemisinine combinations (ACTs) are now widely recom-
mended as ﬁrst-line drugs for the treatment of uncompli-
cated malaria in several African countries. The most
commonly used ACTs in these settings include arteme-
ther–lumefantrine and amodiaquine–artesunate, with dihyd-
roartemisinin–piperaquine also being utilized. Data on the
safety and efﬁcacy of antimalarials in HIV-infected popula-
tions are still limited (Table 2). Only a few recent studies
TABLE 1. Review of human immunodeﬁciency virus-1
infection and non-severe clinical malaria incidence
First
author,
year Risk of symptomatic malaria Remarks
Witworth,
2000 [34]
OR: 6.0, 3.4 and 1.2 for CD4 cell counts of
<200/lL, 200–499/lL, and ≥500/lL,
respectively
Any symptomatic
parasitaemia
French,
2001 [35]
Absolute Risk: 140, 93 and 57 per 1000
person-years for CD4 cell counts of
<200/lL and 200–499/lL, and ≥500
parasites/lL, respectively
Any symptomatic
parasitaemia
French,
2001 [35]
Absolute Risk: 90, 53 and 22 per 1000
person-years for CD4 cell counts of
<200/lL, 200–499/lL and ≥500/lL,
respectively
Symptomatic
parasitaemia
with >2800
parasites/lL
Laufer,
2006 [37]
Relative risks of 4.4 and 3 for CD4 cell counts
of <200/lL and 200–499/lL, respectively, as
compared with a CD4 cell count of ≥500/lL
Patnaik,
2005 [36]
OR: 5.4, 4.9 and 3.2 per 1000 person-years for
CD4 cell counts of <200/lL and 200–499/lL,
and ≥400 parasites/lL, respectively
CD4 measures
at baseline
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used ACTs and were able to determime CD4 cell counts. It
has been reported that HIV-1-infected patients with malaria
and with lower CD4 cell counts have a higher risk of
experiencing a recrudescent infection and a new infection
(Fig. 1; Table 2). Taking into account the reciprocal effect of
malaria on CD4 cell count [17] and the results of a
prospective cohort study with availability of baseline CD4
cell count values [36], the cut-off point for an increased risk
of treatment failure, higher parasite prevalence and malarial
fever probably has to be set at ≥400 cells/mL.
With the introduction of ARTs and co-trimoxazole
prophylaxis, the situation is changing drastically. First,
co-trimoxazole has been rediscovered as an antimalarial
[2]. The protective efﬁcacy of co-trimoxazole prophylaxis
against clinical malaria ranges between 46% and 97% in
HIV-1-infected individuals [56,57], and between 39.5% and
99.5% in HIV-negative infants and children [58,59]. The
lowest ﬁgures were observed where malaria transmission
and sulphadoxine–pyrimethamine resistance were extremely
high.
Drug–drug Interactions
Interactions between ARTs and antimalarials also deserve
attention. Interactions may affect antimalarial activity and
exacerbate toxicity. Furthermore, if individuals are exposed
to repeated malaria infections requiring treatment, the effect
of drug interactions combined with the increased transient
viral replication and viral load during malaria infection [27]
may be similar to the effects of suboptimal adherence to
ARTs. The currently used ARTs fall into three classes:
nucleoside reverse transcriptase inhibitors, non-nucleoside
reverse transcriptase inhibitors, and protease inhibitors.
Possible treatment interactions have been discussed previ-
ously [60]. Both malaria and HIV case management involve
combination therapies, and many drugs follow the same
metabolic pathways. Therefore, detailed clinical studies that
also assess pharmacokinetic and pharmacodynamic interac-
tions are needed. Two recent in vivo observations showed
that co-administration of artemether–lumefantrine with efavi-
renz or nevirapine resulted in a reduction in artemether and
dihydroartemisinin exposure, but the ﬁndings on the impact
on lumefantrine were conﬂicting [61,62]. One of the studies
indicated a reduction in nevirapine exposure [62]. Fortu-
nately, safety and tolerability may not be affected [61].
Pharmacokinetic and pharmacodynamic trials evaluating the
impact of these drug interactions are urgently needed, as
treatment efﬁcacy and the selection of resistant strains may
be affected. Another in vivo study showed a dramatic beneﬁt
of the interaction between ritonavir-boosted lopinavir and
artemether–lumefantrine in terms of improved malaria treat-
ment outcomes, with no apparent increase in the risk of
toxicity [63]. Clearly, in these settings, the boosted lopina-
vir-based ART regimen had signiﬁcant advantages over the
non-nucleoside reverse transcriptase inhibitor-based ART
regimen, as it was associated with a marked reduction in
malaria risk. This regimen could therefore be strategically
utilized in high-transmission settings in high-risk populations,
such as children <5 years of age, for the dual beneﬁts of
protection against malaria and as a superior regimen for HIV
treatment [64]. For ARVs combined with amodiaquine–
artesunate, in particular efavirenz, a higher risk of neutrope-
nia has been documented, and cases of hepatitis have been
reported [65,66]. This provides good guidance for clinicians in
their evaluations. There is limited literature on the interac-
tion between quinine and ARVs, but the available literature
does not suggest any obvious contraindications for its use
[67]. Overall, the spectrum of potential adverse events with
concurrent administration of the other antimalarial drugs and
TABLE 2. Human immunodeﬁciency virus-1 (HIV)-1 infection and antimalarial treatment failure
First author, year
Age
(years) Treatment
Follow-
up (days)
HIV-
negative
HIV-
positive PCR CD4 Result
Muller, 1990 [70] <5 CQ–SP 3 40 35   NS
Muller, 1990 [70] 26 CQ–SP 3 58 142   NS
Colebunders, 1990 [71] 7 QN 7 83 59   NS
Greenberg, 1991 [72] <1 SP 7 166 32   NS
Kamya, 2001 [73] <5 CQ 14/28 186 6   NS
Kamya, 2001 [73] 10 CQ 14/28 124 23   NS
Birku, 2002 [74] 32 AS 3   Decreased parasite density and
fever clearance
Kamya, 2006 [75] 28.5 CQ–SP
AQ–SP
AQ–AS
28 113 50 +  Increased total treatment failure
Increase in new infections
Van Geertruyden, 2006 [76] 27.6 SP–AL 28 530 266 + + Increased total treatment failure
in low-CD4 HIV-positive vs. HIV-
negative individuals: NS
PCR: genotyping for recrudescence or new infection.
AL, artemether–lumefantrine; AQ, amodiaquine; AS, artesunate or artemisinine; CQ, chloroquine; NS, not signiﬁcant; QN, quinine; SP, sulphadoxine–pyrimethamine.
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ARVs is not well characterized. Adjustment of antimalarial
dosing may be necessary to avoid toxicity, but adequate data
to guide dosing adjustments are under investigation and not
yet available. These will need standardized evaluations to
ensure that any such events are consistently documented.
This will become increasingly important with the develop-
ment of newer antimalarial drugs and ARVs. The strategies
for controlling malaria during pregnancy rely on case
management and a package of preventive measures, including
insecticide-treated bed-nets (ITNs) and intermittent preven-
tive treatment with sulphadoxine–pyrimethamine, a folate
inhibitor [68]. HIV-1 infection decreases the efﬁcacy of
sulphadoxine–pyrimethamine intermittent preventive treat-
ment during pregnancy [69]. Co-trimoxazole prophylaxis is
currently recommended by the WHO to prevent opportu-
nistic infections in pregnant women living with HIV/AIDS. In
HIV-infected pregnant women on daily co-trimoxazole,
sulphadoxine–pyrimethamine intermittent preventive treat-
ment is not indicated, as it may be associated with
overlapping toxicities. Fortunately, co-trimoxazole prophy-
laxis has been shown to decrease the prevalence of placental
malaria in HIV-infected women as much as sulphadoxine–
pyrimethamine intermittent preventive treatment in
HIV-uninfected women [2].
Conclusion
For the prevention and treatment of malaria in HIV-infected
populations, the current standard of care should include the
wide availability of ITNs, the use of co-trimoxazole prophy-
laxis, the wide availability of different ACTs and intermittent
preventive treatment with sulphadoxine–pyrimethamine or
co-trimoxazole in pregnant women. For the treatment of HIV
infection, the increasing availability and rapid scale-up of ARV
therapy has ensured wider coverage of the population that
requires this treatment. The available data show that the
wider implementation of multiple interventions such as ITNs,
co-trimoxazole prophylaxis and ARV therapy may substan-
tially reduce the morbidity of malaria in HIV-infected patients
[3,56]. HIV infection may therefore no longer be considered
to be a risk factor for malaria among those accessing care for
HIV infection, as such individuals are now, paradoxically,
protected from malaria by co-trimoxazole prophylaxis and
ITNs. These ﬁndings therefore highlight the need for
conﬁrmatory diagnosis of malaria in HIV-infected individuals
receiving these interventions, and the provision of malaria
therapy only when the diagnosis is conﬁrmed. The fact that
protease inhibitors have proven antimalarial properties may
have huge public health implications regarding the potential
beneﬁt of this kind of interaction for co-infected individuals,
particularly those living in areas of high malaria transmission
intensity.
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